Show simple item record

dc.contributor.authorMalekizadeh, Y
dc.contributor.authorWilliams, G
dc.contributor.authorKelson, M
dc.contributor.authorWhitfield, D
dc.contributor.authorMill, J
dc.contributor.authorCollier, D
dc.contributor.authorBallard, C
dc.contributor.authorJeffries, A
dc.contributor.authorCreese, B
dc.date.accessioned2020-09-14T10:46:44Z
dc.date.issued2020-08-22
dc.description.abstractBackground: Stroke/thromboembolic events, infections, and death are all significantly increased by antipsychotics in dementia but little is known about why they can be harmful. Using a novel application of a drug repurposing paradigm, we aimed to identify potential mechanisms underlying adverse events. Methods: Whole transcriptome signatures were generated for SH-SY5Y cells treated with amisulpride, risperidone, and volinanserin using RNA sequencing. Bioinformatic analysis was performed that scored the association between antipsychotic signatures and expression data from 415,252 samples in the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) repository. Results: Atherosclerosis, venous thromboembolism, and influenza NCBI GEO-derived samples scored positively against antipsychotic signatures. Pathways enriched in antipsychotic signatures were linked to the cardiovascular and immune systems (eg, brain derived neurotrophic factor [BDNF], platelet derived growth factor receptor [PDGFR]-beta, tumor necrosis factor [TNF], transforming growth factor [TGF]-beta, selenoamino acid metabolism, and influenza infection). Conclusions: These findings for the first time mechanistically link antipsychotics to specific cardiovascular and infectious diseases which are known side effects of their use in dementia, providing new information to explain related adverse eventsen_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.description.sponsorshipEngineering and Physical Sciences Research Council (EPSRC)en_GB
dc.identifier.citationVol. 6: e12078en_GB
dc.identifier.doi10.1002/trc2.12078
dc.identifier.grantnumberMC_PC_16072en_GB
dc.identifier.urihttp://hdl.handle.net/10871/122851
dc.language.isoenen_GB
dc.publisherWileyen_GB
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2020 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer’s Associationen_GB
dc.subjectamisulprideen_GB
dc.subjectantipsychoticen_GB
dc.subjectbrain derived neurotrophic factoren_GB
dc.subjectcardiovascularen_GB
dc.subjectimmuneen_GB
dc.subjectplatelet derived growth factoren_GB
dc.subjectrisperidoneen_GB
dc.subjectRNA-seqen_GB
dc.subjectseleniumen_GB
dc.subjectside effectsen_GB
dc.subjecttumor necrosis factoren_GB
dc.titleWhole transcriptome in-silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side-effectsen_GB
dc.typeArticleen_GB
dc.date.available2020-09-14T10:46:44Z
dc.identifier.issn2352-8737
dc.descriptionThis is the final version. Available from the publisher via the DOI in this record.en_GB
dc.identifier.journalAlzheimer's and Dementia: Translational Research and Clinical Interventionsen_GB
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_GB
dcterms.dateAccepted2020-07-28
exeter.funder::Medical Research Council (MRC)en_GB
exeter.funder::Engineering and Physical Sciences Research Council (EPSRC)en_GB
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-07-28
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2020-07-28T16:40:13Z
refterms.versionFCDAM
refterms.dateFOA2020-09-14T10:46:48Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer’s Association
Except where otherwise noted, this item's licence is described as This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2020 The Authors. Alzheimer’s & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer’s Association